orladeyo
(Berotralstat hydrochloride)BioCryst Pharmaceuticals Inc.
Usage: ORLADEYO® is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older. It is not approved for treating acute HAE attacks, and higher doses than 150 mg daily are not recommended due to potential QT prolongation risks.